NEW YORK, April 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has successfully achieved the halfway mark for total enrollment in its ongoing plecanatide Phase II/III clinical trial in chronic idiopathic constipation (CIC) patients. Over 800 patients have been screened at present, resulting in a total of 440 randomized, enrolled patients to date. The trial, designed to enroll 880 patients to achieve 800 evaluable patients, was initiated on October 24, 2011. The Company anticipates completing enrollment of the trial in the third quarter of this year and reporting top line data in the fourth quarter.